SFG
MLTX icon

SVB Financial Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

SVB Financial Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,173
Closed -$922K – 19
2023
Q3 		$922K Hold
16,173
– – 1.73% 7
2023
Q2 		$825K Hold
16,173
– – 1.56% 9
2023
Q1 		$346K Hold
16,173
– – 0.66% 13
2022
Q4 		$170K Buy
+16,173
New +$144K 0.46% 17

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

SVB Financial Group's MLTX Position: Q4 2023 in Review

SVB Financial Group sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 16,173 shares — an estimated $922K sold.

SVB Financial Group first reported a position in MLTX in Q4 2022 and held it in 4 quarters. The position peaked at $922K in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • SVB Financial Group reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • SVB Financial Group sold 16,173 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $922K.
  • SVB Financial Group first reported a position in MoonLake Immunotherapeutics in Q4 2022 and held it in 4 quarters.
  • SVB Financial Group's MoonLake Immunotherapeutics position peaked at $922K in Q3 2023.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on SVB Financial Group's 13F filing for Q4 2023, filed 14 Feb 2024.